Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    The LuMEn study 177Lu-octreotate treatment outcome prediction using Multimodality imaging in refractory neuroEndocrine tumours

    Summary
    EudraCT number
    2012-003666-41
    Trial protocol
    BE  
    Global end of trial date
    16 Sep 2022

    Results information
    Results version number
    v1(current)
    This version publication date
    13 Oct 2024
    First version publication date
    13 Oct 2024
    Other versions
    Summary report(s)
    Final Study Report

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    IJBMNLUMEN
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01842165
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Institut Jules Bordet
    Sponsor organisation address
    rue Meylemeersch 90, Anderlecht, Belgium, 1200
    Public contact
    Ioannis Karfis, Jules Bordet Institute, +32 25413178, ioannis.karfis@bordet.be
    Scientific contact
    Ioannis Karfis, Jules Bordet Institute, +32 25413178, ioannis.karfis@bordet.be
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    24 Aug 2023
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    20 May 2022
    Global end of trial reached?
    Yes
    Global end of trial date
    16 Sep 2022
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    For each lesion: To assess the value of the following parameters (obtained through functional and molecular imaging) for predicting the lesion-by-lesion PRRT treatment outcome: - 18FDG uptake on 18FDG PET/CT, - 68Ga-octreotate uptake on 68Ga-octreotate PET/CT, - Apparent Diffusion Coefficient on Diffusion Weighted-MRI, [for these three parameters, absolute values at baseline will be assessed] - Tumor dosimetry on post-177Lu-octreotate SPECT/CT after the first cycle.
    Protection of trial subjects
    a nephroprotective perfusion of an amino acid solution was simultaneously administered with the 177Lu-octreotate injection. This nephroprotective perfusion was preceded by the administration of an anti-emetic regiment to prevent nausea or vomiting from the amino acids.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    25 Jul 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Belgium: 37
    Worldwide total number of subjects
    37
    EEA total number of subjects
    37
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    13
    From 65 to 84 years
    24
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Screening procedures were done within 4 weeks before the first 177Lu-octreotate injection.

    Period 1
    Period 1 title
    Treatment (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    77Lu-octreotate
    Arm description
    This treatment consisted of 177Lu-octreotate injections(4 cycles) in fixed activities of 7,4GBq (200 mCi) (±5%) each, given 12 weeks (±1week) apart, injected intravenously, simultaneously with nephroprotective perfusion of an amino acid solution.
    Arm type
    Experimental

    Investigational medicinal product name
    Lu-octreotate
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Radiopharmaceutical precursor, solution
    Routes of administration
    Injection
    Dosage and administration details
    (4 cycles) in fixed activities of 7,4GBq (200 mCi) (±5%) each, given 12 weeks (±1week) apart, injected intravenously, simultaneously with nephroprotective perfusion of an amino acid solution

    Number of subjects in period 1
    77Lu-octreotate
    Started
    37
    Completed
    28
    Not completed
    9
         Consent withdrawn by subject
    3
         Second primary malignancy
    2
         Disease progression
    2
         Death
    1
         Lost to follow-up
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Treatment
    Reporting group description
    -

    Reporting group values
    Treatment Total
    Number of subjects
    37 37
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    13 13
        From 65-84 years
    24 24
        85 years and over
    0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    66 ( 8.1 ) -
    Gender categorical
    Units: Subjects
        Female
    18 18
        Male
    19 19
    tumour grade
    Units: Subjects
        grade 1
    12 12
        grade 2
    22 22
        grade 3
    3 3
    primary tumour site
    Units: Subjects
        small intestinal
    23 23
        pancreatic
    10 10
        colorectal
    4 4
    site of metastasis: liver
    Units: Subjects
        Yes
    32 32
        No
    5 5
    site of metastases: lymph nodes
    Units: Subjects
        Yes
    31 31
        No
    6 6
    site of metastasis: bone
    Units: Subjects
        Yes
    22 22
        No
    15 15
    site of metastases: peritoneum
    Units: Subjects
        Yes
    12 12
        No
    25 25
    site of metastases : pancreas
    Units: Subjects
        Yes
    3 3
        No
    34 34
    site of metastasis: lung
    Units: Subjects
        Yes
    2 2
        No
    35 35
    site of metastases: other (pleural, adrenal, ovarium, mesentery/pelvic)
    Units: Subjects
        Yes
    6 6
        No
    31 31
    symptoms: diarrhoea
    Units: Subjects
        Yes
    16 16
        No
    21 21
    symptoms: pain
    Units: Subjects
        Yes
    15 15
        No
    22 22
    symptoms: fatigue
    Units: Subjects
        Yes
    11 11
        No
    26 26
    symptoms: flushes
    Units: Subjects
        Yes
    9 9
        No
    28 28
    No symptoms
    Units: Subjects
        Yes
    12 12
        no
    25 25
    Positive 18FDG-PET/CT
    Units: Subjects
        Yes
    15 15
        No
    22 22
    surgery (including primary tumour resection)
    Units: Subjects
        Yes
    27 27
        No
    10 10
    SSAs
    Units: Subjects
        Yes
    36 36
        No
    1 1
    targeted therapy (including everolumus and sunitinib)
    Units: Subjects
        Yes
    11 11
        No
    26 26
    liver targeted therapy (including chemo-embolisation, radio-embolisation and radiofrequency ablation
    Units: Subjects
        Yes
    8 8
        No
    29 29
    radiotherapy (external beam radiation)
    Units: Subjects
        Yes
    4 4
        No
    33 33
    interferon
    Units: Subjects
        Yes
    1 1
        No
    36 36

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    77Lu-octreotate
    Reporting group description
    This treatment consisted of 177Lu-octreotate injections(4 cycles) in fixed activities of 7,4GBq (200 mCi) (±5%) each, given 12 weeks (±1week) apart, injected intravenously, simultaneously with nephroprotective perfusion of an amino acid solution.

    Primary: Lesion time to progression (TTP) (lesion-based analysis)

    Close Top of page
    End point title
    Lesion time to progression (TTP) (lesion-based analysis) [1]
    End point description
    116 target lesions. 84 out of 116 were considered evaluable. 1) 18FDG PET/CT imaging: No significant association with the lesion morphological outcome was observed for any of the 18FDG PET baseline parameters. 2) 68Ga-DOTATATE PET/CT imaging: Baseline SUVmax, SUVmean, tumour-to-blood ratio, SSTR-TV and total lesion SSTR expression were not associated with the lesion morphological outcome. 3) dwMR imaging: In 62 morphologically evaluable lesions, no association was found between baseline ADC and lesion outcome (p=0.58).
    End point type
    Primary
    End point timeframe
    Median follow-up time for all subjects (data analysis in July 2022) was 57 months (95%CI: 50-71), during which the median lesion-based TTP was not reached.
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This is a single arm study.
    End point values
    77Lu-octreotate
    Number of subjects analysed
    37 [2]
    Units: evaluable target lesions
        complete response
    0
        partial response
    22
        stable
    50
        progression
    12
    Notes
    [2] - 84 evaluable target lesions
    No statistical analyses for this end point

    Secondary: objective response (patient-based analysis)

    Close Top of page
    End point title
    objective response (patient-based analysis)
    End point description
    End point type
    Secondary
    End point timeframe
    The median follow-up time (data cutoff, July 2022) was 57 months (95% CI, 50–71 months).
    End point values
    77Lu-octreotate
    Number of subjects analysed
    37 [3]
    Units: number of patients
        complete response
    0
        partial response
    11
        stable disease
    24
        progression
    2
    Notes
    [3] - 37 treated patients
    No statistical analyses for this end point

    Secondary: Progression-free survival

    Close Top of page
    End point title
    Progression-free survival
    End point description
    Patients with pancreatic primary NETs had a shorter PFS (median, 19.4 months) than that of patients with intestinal NETs (29.5 months) (P-value=0.01; HR,2.96; 95% CI, 1.25–7.02). 1) 68Ga-DOTATATE PET/CT: An SSTR TV decrease of more than 10% from baseline after C1 discriminated patients with a significantly longer median PFS (51.3 months) than that (22.8 months) of patients for whom SSTR TV increased or decreased by less than 10% (P-value=0.003; HR, 0.35; 95% CI, 0.16–0.75). 2) 18F-FDG PET/CT. Quantification of baseline 18F-FDG PET/CT was available for only 10 patients. Because of the low number of patients and events, no statistical analysis for association with patient outcome was performed. 3) Diffusion-Weighted MRI: In 29 patients followed by MRI, there was no statistical evidence of an association between baseline ADC or its relative change after C1 and patient outcome.
    End point type
    Secondary
    End point timeframe
    Median follow-up: 57 months
    End point values
    77Lu-octreotate
    Number of subjects analysed
    37 [4]
    Units: months
        median (inter-quartile range (Q1-Q3))
    28.1 (21.7 to 48.1)
    Notes
    [4] - treated patients
    No statistical analyses for this end point

    Secondary: tumor dosimetry

    Close Top of page
    End point title
    tumor dosimetry
    End point description
    83 target lesions: The median absorbed dose in C1 was 33Gy (IQR, 22–50 Gy) and declined from the first to the last treatment cycles, reaching significance between C1 and cycle 3 (P-value=0.002), C1 and cycle 4 (P-value<0.001), and cycles 2 and 4 (P-value=0.01). A significant correlation between tumor-absorbed C1 dose and lesion outcome was demonstrated for larger lesions (>=22mm) and for the limited number of lesions of colorectal primary NET origin. On a patient level, the minimal absorbed dose per target lesion in C1 ranged from 10 to 77Gy. An optimal cutoff of 35Gy (i.e., patients in whom all target lesions received at least a 35-Gy tumor-absorbed C1 dose) discriminated patients with a significantly longer median PFS (48.1 months) than that of patients in whom at least 1 target lesion was treated with less than 35Gy in C1 (26.2 months) (P-value=0.02; HR, 0.37; 95% CI, 0.17–0.82).
    End point type
    Secondary
    End point timeframe
    absorbed dose in C1 (cycle 1)
    End point values
    77Lu-octreotate
    Number of subjects analysed
    37 [5]
    Units: Gy
        median (inter-quartile range (Q1-Q3))
    33 (22 to 50)
    Notes
    [5] - treated patients
    No statistical analyses for this end point

    Other pre-specified: Glomerular filtration rate (GFR) decrease between start and end of treatment

    Close Top of page
    End point title
    Glomerular filtration rate (GFR) decrease between start and end of treatment
    End point description
    End point type
    Other pre-specified
    End point timeframe
    end of treatment, median follow-up of 23 months.
    End point values
    77Lu-octreotate
    Number of subjects analysed
    37 [6]
    Units: relative decrease (%)
        median (inter-quartile range (Q1-Q3))
    -11 (-17 to 3)
    Notes
    [6] - treated patients
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    from the first administration of 177Lu-octreotate until 12 weeks after the last dose of 177Lu-octreotate
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26
    Reporting groups
    Reporting group title
    Exposed to 177Lu-octreotate:
    Reporting group description
    -

    Serious adverse events
    Exposed to 177Lu-octreotate:
    Total subjects affected by serious adverse events
         subjects affected / exposed
    13 / 37 (35.14%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Myelodysplastic syndrome
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Incisional hernia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Spinal compression fracture
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Cardiac failure
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Inflammation
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pyrexia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Immune system disorders
    Anaphylactic reaction
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Ascites
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Intestinal ischaemia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pancreatitis acute
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Subileus
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Hepatobiliary disorders
    Cholecystitis acute
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Hydronephrosis
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Bacteroides infection
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Exposed to 177Lu-octreotate:
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    37 / 37 (100.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Skin papilloma
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Vascular disorders
    Flushing
         subjects affected / exposed
    4 / 37 (10.81%)
         occurrences all number
    9
    Hot flush
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Hypertension
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Hypotension
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    General disorders and administration site conditions
    Catheter site pain
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Catheter site pruritus
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Fatigue
         subjects affected / exposed
    19 / 37 (51.35%)
         occurrences all number
    22
    Induration
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Infusion site extravasation
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Malaise
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Oedema
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Oedema peripheral
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Pyrexia
         subjects affected / exposed
    4 / 37 (10.81%)
         occurrences all number
    4
    Reproductive system and breast disorders
    Benign prostatic hyperplasia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Prostatitis
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Vaginal haemorrhage
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Hiccups
         subjects affected / exposed
    3 / 37 (8.11%)
         occurrences all number
    5
    Hypoventilation
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Pleural effusion
         subjects affected / exposed
    3 / 37 (8.11%)
         occurrences all number
    4
    Wheezing
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Depression
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Insomnia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    4
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    10 / 37 (27.03%)
         occurrences all number
    16
    Activated partial thromboplastin time ratio increased
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Aspartate aminotransferase increased
         subjects affected / exposed
    9 / 37 (24.32%)
         occurrences all number
    17
    Blood alkaline phosphatase increased
         subjects affected / exposed
    7 / 37 (18.92%)
         occurrences all number
    11
    Blood bilirubin increased
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Blood cholesterol increased
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    12 / 37 (32.43%)
         occurrences all number
    22
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    2
    International normalised ratio increased
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    2
    Lymphocyte count decreased
         subjects affected / exposed
    24 / 37 (64.86%)
         occurrences all number
    32
    Lymphocyte count increased
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Neutrophil count decreased
         subjects affected / exposed
    4 / 37 (10.81%)
         occurrences all number
    6
    N-terminal prohormone brain natriuretic peptide increased
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Platelet count decreased
         subjects affected / exposed
    19 / 37 (51.35%)
         occurrences all number
    41
    Weight decreased
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Weight increased
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    White blood cell count decreased
         subjects affected / exposed
    12 / 37 (32.43%)
         occurrences all number
    23
    Injury, poisoning and procedural complications
    Contusion
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Spinal compression fracture
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Congenital, familial and genetic disorders
    Phimosis
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Cardiac disorders
    Mitral valve incompetence
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Tricuspid valve sclerosis
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Ventricular arrhythmia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Nervous system disorders
    Carpal tunnel syndrome
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Dysgeusia
         subjects affected / exposed
    4 / 37 (10.81%)
         occurrences all number
    6
    Headache
         subjects affected / exposed
    7 / 37 (18.92%)
         occurrences all number
    7
    Paresis
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Presyncope
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    23 / 37 (62.16%)
         occurrences all number
    47
    Hilar lymphadenopathy
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Leukocytosis
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Ear and labyrinth disorders
    Tinnitus
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Vertigo
         subjects affected / exposed
    4 / 37 (10.81%)
         occurrences all number
    5
    Eye disorders
    Cataract
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Eye disorder
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Glaucoma
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Visual field defect
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Visual impairment
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Vitreous detachment
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    6 / 37 (16.22%)
         occurrences all number
    9
    Abdominal pain lower
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Abdominal pain upper
         subjects affected / exposed
    5 / 37 (13.51%)
         occurrences all number
    8
    Chronic gastritis
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Constipation
         subjects affected / exposed
    9 / 37 (24.32%)
         occurrences all number
    11
    Diarrhoea
         subjects affected / exposed
    10 / 37 (27.03%)
         occurrences all number
    12
    Diverticulum
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Dry mouth
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Dyspepsia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Dysphagia
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Gastric ulcer
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Gastritis
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Gastrointestinal pain
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Gastrooesophageal reflux disease
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Haemorrhoidal haemorrhage
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Hiatus hernia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Intestinal obstruction
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Nausea
         subjects affected / exposed
    15 / 37 (40.54%)
         occurrences all number
    28
    Reflux gastritis
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Vomiting
         subjects affected / exposed
    11 / 37 (29.73%)
         occurrences all number
    18
    Hepatobiliary disorders
    Ocular icterus
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    17 / 37 (45.95%)
         occurrences all number
    23
    Dermatitis allergic
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Eczema
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Erythema
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Hirsutism
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Hyperhidrosis
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Pruritus
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    4
    Urticaria
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    3
    Renal and urinary disorders
    Chronic kidney disease
         subjects affected / exposed
    3 / 37 (8.11%)
         occurrences all number
    3
    Micturition urgency
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Pollakiuria
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Urethral stenosis
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Endocrine disorders
    Hypothyroidism
         subjects affected / exposed
    3 / 37 (8.11%)
         occurrences all number
    3
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    5 / 37 (13.51%)
         occurrences all number
    5
    Back pain
         subjects affected / exposed
    4 / 37 (10.81%)
         occurrences all number
    4
    Bone pain
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Joint stiffness
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Myalgia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Pain in extremity
         subjects affected / exposed
    3 / 37 (8.11%)
         occurrences all number
    3
    Periarthritis
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Spinal pain
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    4 / 37 (10.81%)
         occurrences all number
    4
    Folliculitis
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Gastroenteritis
         subjects affected / exposed
    3 / 37 (8.11%)
         occurrences all number
    3
    Infection
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Otitis media
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Pneumonia mycoplasmal
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Post procedural infection
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Respiratory tract infection
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Skin infection
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Upper respiratory tract infection
         subjects affected / exposed
    4 / 37 (10.81%)
         occurrences all number
    6
    Urinary tract infection
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    2
    Wound infection
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    3
    Hypercalcaemia
         subjects affected / exposed
    2 / 37 (5.41%)
         occurrences all number
    3
    Hypercholesterolaemia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Hyperkalaemia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Hyperuricaemia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    2
    Hypocalcaemia
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Iron deficiency
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1
    Vitamin D deficiency
         subjects affected / exposed
    1 / 37 (2.70%)
         occurrences all number
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    20 Dec 2012
    protocol v2.0 ICF v2.0
    27 May 2013
    Protocol v3.0 ICF v3.1
    07 Nov 2013
    Protocol v3.3 ICF v3.1
    05 Jun 2014
    Protocol v4.0 ICF v4.0
    24 Jun 2015
    Protocol v5.0 ICF v5.1
    17 Sep 2015
    Protocol v6.0 ICF v6.0
    22 Oct 2015
    Addendum A & B
    28 Sep 2016
    Protocol v7.2 ICF v7.0 Addendum C v1.0
    22 Jun 2017
    RSI change
    06 Dec 2018
    ICF v8.0 GDPR information letter
    17 Jun 2021
    Protocol v8.0
    21 Oct 2021
    Institut Jules Bordet move
    09 Mar 2022
    new insurer

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 05:45:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA